At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 632 enrolled
Drug / intervention
semaglutide +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes
In Brief
A Phase 2 clinical trial evaluating semaglutide and oral placebo for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 632 participants across 103 sites in 14 countries.
Detailed Summary
This trial is conducted globally. The aim of the trial is to examine the dose range, escalation and efficacy of oral semaglutide in subjects with type 2 diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesAustria, Bulgaria, Canada, Denmark, Germany, Israel, Italy, Malaysia, Serbia, South Africa, Spain, Sweden, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedAug 2013
Enrollment StartDec 2013
Primary CompletionDec 2014
TodayJul 2026
First PostedAug 15, 2013
Enrollment StartDec 2, 2013
Primary CompletionDec 11, 2014
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 12.9 years ago
Interventions
semaglutidedrug
Once-daily oral administration as tablets.
semaglutidedrug
Once-weekly,injected s.c./subcutaneously (under the skin) using a pen
oral placebodrug
Once-daily oral administration as tablets.